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Abstract: 
Recent years have seen considerable progress in epidemiological and molecular genetic research 
into environmental and genetic factors in schizophrenia, but methodological uncertainties remain 
with regard to validating environmental exposures, and the population risk conferred by 
individual molecular genetic variants is small. There are now also a limited number of studies 
that have investigated molecular genetic candidate gene-environment interactions (G × E), 
however, so far, thorough replication of findings is rare and G × E research still faces several 
conceptual and methodological challenges. In this article, we aim to review these recent 
developments and illustrate how integrated, large-scale investigations may overcome 
contemporary challenges in G × E research, drawing on the example of a large, international, 
multi–center study into the identification and translational application of G × E in schizophrenia. 
While such investigations are now well underway, new challenges emerge for G × E research 
from late-breaking evidence that genetic variation and environmental exposures are, to a 
significant degree, shared across a range of psychiatric disorders, with potential overlap in 
phenotype. 
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Article: 
The Environment and Schizophrenia: Evidence Beyond Reasonable Doubt? 
Over the past decades, substantial and consistent evidence has accrued that implicates 
environmental factors in the development of schizophrenia. Numerous studies have consistently 
reported an increased incidence of schizophrenia in urban areas1–8 as well as in migrant and 
minority ethnic groups.4,7,9–12 Evidence further suggests cannabis use13–17 and childhood 
adversity18–20 confer substantial risk for psychotic disorder. For these environmental factors, 
pooled effects sizes from meta-analyses in the range of a 2- to 4-fold increase in risk,4,5,8–10,13–
17,20evidence of dose-response gradient,10,20–26 and population attributable risk fractions of 20%–
35%20,27 have been reported. These advances notwithstanding, a number of methodological 
uncertainties remain in validating environmental exposures, including risk of systematic 
information bias, confounding by genetic and other factors, and possible reverse causality.19,28–32 
Recent Gene Discoveries in Schizophrenia: (Some) More Light in the Dark 
While the initial surge for the molecular genetic basis of schizophrenia was characterized by 
slow progress and methodological concerns,32,33recent years have seen more rapid advances 
through large-scale collaboration in genome-wide association studies (GWAS), which have 
generated replicated findings on a number of common risk alleles.34–38Recent advances have 
further produced consistent findings that rare copy number variants (CNVs) increase 
schizophrenia risk substantially and to a greater extent than individual common risk alleles 
identified by GWAS.39–42 
However, the common variants identified to date explain only a small proportion of the genetic 
risk of schizophrenia and a large number of common risk alleles (with small effects) remain to be 
identified.35,41,43Also, heritability estimates of the overall contribution of common genetic 
variants based on molecular genetic data are considerably smaller (ie 23%–33%)38,44 than 
heritability estimates from twin studies (ie 81%).45,46What is more, while the reported effect sizes 
for CNVs tend to be much larger, they are rare and therefore contribute even less to total risk.40–
42There are several potential explanations that may account for this pattern in molecular genetic 
findings, but, given the consistent evidence that environmental factors confer substantial, and 
much greater risk than individual common genetic risk variants, it seems reasonable that gene-
environment interactions (G × E) play an important role. 
Gene-Environment Interactions: Contemporary Challenges 
The G × E approach posits that the effect of an individual’s genotype depends on environmental 
exposure and, vice versa, the effect of environmental exposure on risk depends on an 
individual’s genotype.32,47 Since both environmental and genetic factors have consistently been 
implicated in etiology, but there is considerable variation in phenotype, in so far as not all 
individuals exposed to environmental risk or carrying genetic risk variants go on to develop the 
disorder, G × E appears to be particularly relevant in schizophrenia.29,48G × E would also 
plausibly account for the large discrepancy in heritability estimates from twin and molecular 
genetic studies.44–46 This heritability gap may come about because G × E involving shared 
environmental factors within families are included in heritability estimates of twin studies, but 
not molecular genetic studies of unrelated subjects.46 
While long ignored in molecular genetic analyses, and still an emerging field, the beginning of 
this century has seen a limited number of G × E studies on candidate genes in 
schizophrenia.29,49,50 These studies have tested individual, a priori selected single-nucleotide 
polymorphisms (SNPs), with very few attempts at replication49–52 and limited evidence on the 
potential mechanisms underlying G × E in schizophrenia.31,32 Indeed, there remain a number of 
conceptual and methodological challenges in contemporary molecular G × E research. These 
include (a) the validation of environmental exposures, consistently measured in sufficiently 
large, epidemiologically characterized samples for G × E analysis33,46; (b) selecting optimal 
strategies for (1) the use of complex GWAS data, (2) a priori, hypothesis-based vs exploratory 
approaches, and (3) the type of genetic variation to be used in G × E analysis; (c) a relative 
paucity of validated and scalable experimental methods for investigating modifiable mechanisms 
underlying G × E in schizophrenia; (d) the different phenotypic levels of schizophrenia at which 
G × E may impact, including intermediate phenotypes, prodrome, onset, severity, and course of 
schizophrenia; (e) statistical modeling of the likely simultaneous presence of G × E, G × G and E 
× E interactions; (f) ethical issues that may arise if G × E analyses produce evidence of 
substantial risks to be leveraged in risk assessment and early prediction; and (g) the need for 
translation of G × E findings to clinical practice. 
It has repeatedly been noted that current challenges in molecular genetic G × E research warrant 
integrated, large-scale investigations that bring together international experts at the forefront of 
research in epidemiology, genetics, experimental psychiatry, statistics, social psychiatry, brain 
imaging, and clinical psychiatry.31–33,47,50,53 While in molecular genetic research large-scale 
collaborations such as the International Schizophrenia Consortium35 or the Psychiatric Genomics 
Consortium54 are increasingly common, there are only few examples in G × E research; one is 
“The European Network of National Networks studying Gene-Environment Interactions in 
Schizophrenia” (EU-GEI)32,47(see also www.eu-gei.eu). 
The European Network of National Schizophrenia Networks Studying Gene-Environment 
Interactions (EU-GEI) 
EU-GEI is a large, international, multi–center study of G × E in schizophrenia using family-
based, multidisciplinary research paradigms in more than 15 countries (the Netherlands, the UK, 
Germany, Turkey, Spain, France, Belgium, Greece, Austria, Switzerland, Hong Kong (China), 
Brazil, Australia, Ireland, Italy, and other European and non-European countries represented by 
EU-GEI affiliated centers) for testing a priori G × E hypotheses. The overall aim of EU-GEI is 
the identification and translational application of clinical, genetic, and environmental interactions 
in the development, severity, and course of schizophrenia in patients and their families. To this 
end, several work packages are currently underway that amalgamate expertise from multiple 
disciplines for addressing contemporary challenges in G × E research (see figure 1). 
 
Fig. 1.General approach and overview of European Network of National Networks studying 
Gene-Environment Interactions in Schizophrenia. 
The “Functional Enviromics” work package has developed and currently applies methods for the 
detailed assessment of candidate, individual- and area-level environmental exposures of public 
health relevance (ie with the largest attributable fractions and most relevant to the EU study 
population).12 The work package employs a number of strategies for validating environmental 
exposures by using an optimum, family-based, case-control design in a diverse range of settings 
across Europe, drawing on corroborative sources of information in the assessment of childhood 
and adult adversity to minimize recall bias, and taking account of potential confounding by direct 
and indirect measures of genetic risk as well as other relevant factors. In doing so, “Functional 
Enviromics” aims to investigate the impact of hypothesized individual- and area-level 
environmental exposures on risk of first episode psychosis and to identify proximal explanatory 
factors that account for high rates of psychotic disorder in urban areas and in migrant and ethnic 
minority groups. The work package further aims, together with “Discovery Genetics” and “G × E 
Data & Statistics,” to examine evidence for hypothesized G × E and environment × environment 
(E × E) interactions. 
The “Discovery Genetics” work package aims to identify novel genes and biological pathways 
and implement new approaches for CNVs that will allow, jointly with all other work packages, 
to test specific, a priori G × E hypotheses. Specifically, this work package combines available 
with newly generated GWAS data to identify common variants, showing robust genome-wide 
evidence for association, to test specific, a priori SNP-based G × E hypotheses. “Discovery 
Genetics” further constructs, in collaboration with “G × E Data & Statistics,” polygenic pathway 
scores based on pathway-wide evidence for association of SNPs in genes that are involved in 
specific biological pathways underlying environmental risks. In addition, this work package 
targets previously identified candidate G × E for replication, develops and implements new 
approaches to G × E analysis with CNVs, and conducts proof of principle for genome-wide G × 
E analysis, with the aim of identifying novel risk-environment interplays that are not predicated 
upon the existence of observed genetic main effects. 
In the “Experimental G × E” work package, validated and scalable experimental methods have 
been developed for investigating neural, cognitive, and affective mechanisms underlying the 
interplay of genetic and environmental factors under experimental conditions, controlling for 
measured and unmeasured confounding factors, including genetic factors (and, thereby, gene-
environment correlation). Work by the experimental G × E work package also supports the view 
that epidemiologically validated risk factors such as migration or urban living and upbringing 
have a social component, as proposed by the social defeat hypothesis.55 Specifically, findings 
from this work package suggest a specific impact of social stress on activation in a perigenual 
cingulate-amygdalar circuit in healthy populations exposed to urban living and upbringing56 and 
migration.57This suggests that this circuit may be a core convergence region for risk of mental 
disorders arising through social stressors.58 The experimental G × E approach is also of 
considerable potential value for generating translational knowledge. Therefore, this work 
package has developed innovative Momentary Assessment Technology (ie the PsyMate) to 
investigate stress sensitivity in daily life as an important affective mechanism underlying 
environmental and genetic risk in the development of schizophrenia.59 
The “G × E Prodrome,” “G × E Vulnerability and Severity,” and “G × E Course” work packages 
take into account the different phenotypes and clinical stages of disorder at which gene-
environment interactions may impact, including intermediate phenotypes, prodrome, onset, 
severity, and course of schizophrenia. These work packages aim to investigate clinical, 
environmental, and genetic determinants as well as G × E at all these levels, with initial evidence 
of candidate SNP × cannabis interaction for psychosis liability.60,61 The “G × E Data & 
Statistics” work package provides coordination and support for statistical methodology to 
examine, jointly with all other work packages, G × E, G × G, and E × E interactions underlying 
disease risk, course, and outcome of schizophrenia. The work package further develops novel 
statistical software and methodology for examining G × E interactions. In the “Training” work 
package, a web-based training environment has been developed for addressing a key issue in 
large multi–national collaborations, i.e. inter-rater reliability in the assessment of environmental 
exposures, diagnosis, intermediate phenotypes, prodrome, onset, severity, and course. Given the 
potential ethical issues raised by G × E research in schizophrenia, the “Ethics” work package 
explores these, detects potential needs for regulation and, in collaboration with the 
“Dissemination” work package, will include ethical and legal perspectives in the dissemination 
activities. Lastly, the entire project is coordinated by the “Management” work package. 
Evidence on G × G, G × E, and E × E generated by EU-GEI will aggregate in the development 
of risk prediction algorithms that will be implemented in innovative, translational risk 
assessment charts and momentary assessment technology for early prediction of intermediate 
phenotypes, persistent symptoms, transition to, as well as onset, severity, course, and outcome 
of, schizophrenia. Application of these tools will allow the targeting of prevention, treatment and 
resources to modifiable mechanisms as well as subgroups of individuals with the greatest 
vulnerability, highest risk of developing persistent symptoms and psychotic disorder and, once 
diagnosed, to those with greatest severity and highest risk of poor course and outcome. 
Conclusion and Future Prospects 
Recent years have seen significant advances in epidemiological and molecular genetic research, 
consistently implicating environmental and genetic factors in the etiology of schizophrenia. 
However, methodological uncertainties remain with regard to validating environmental 
exposures and the population risk conferred by the molecular genetic variants identified to date 
remains small. While G × E may account for the latter, so far, replication of the limited number 
of molecular genetic candidate G × E findings is rare. Important conceptual and methodological 
challenges of G × E research in schizophrenia are currently being addressed in integrated, large-
scale investigations, such as EU-GEI. 
While EU-GEI is now well underway, new challenges emerge at the horizon of G × E research. 
It now appears increasingly likely that genetic variation44 and environmental exposures (such as 
childhood adversity)18are, to a significant degree, shared across a range of psychiatric disorders, 
with some emerging evidence of overlap in phenotypes.62 Therefore, as for mono-disciplinary, 
epidemiological and molecular-genetic research, the study of G × E needs to be extended beyond 
individual disorders to investigations of all major psychiatric disorders in order to unpick the 
complex interplay of genes, environment, and underlying mechanisms that push some people 
along a pathway to psychosis, whilst others to non-psychotic or no disorder. Not only cross-
discipline, but also large-scale cross-disorder investigations are now required to more fully 
realize the potential of G × E research in elucidating the etiology of, and, ultimately, improving 
prevention and treatment for, schizophrenia. 
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